Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
Jolien M. Bueno-de-Mesquita(The Netherlands Cancer Institute), Wim H. van Harten(The Netherlands Cancer Institute), Valesca P. Retèl(The Netherlands Cancer Institute), Laura van ‘t Veer(Agendia (Netherlands)), Frits SAM van Dam(The Netherlands Cancer Institute), Kim Karsenberg(The Netherlands Cancer Institute), Kirsten FL Douma(The Netherlands Cancer Institute), Harm van Tinteren(The Netherlands Cancer Institute), Johannes L. Peterse(The Netherlands Cancer Institute), Jelle Wesseling(The Netherlands Cancer Institute), Tin S Wu(The Netherlands Cancer Institute), Douwe E. Atsma(The Netherlands Cancer Institute), Emiel J. Rutgers(The Netherlands Cancer Institute), Guido Brink(Agendia (Netherlands)), Arno Floore(Agendia (Netherlands)), Annuska M. Glas(Agendia (Netherlands)), Rudi M. H. Roumen(Radboud University Nijmegen), Frank E. Bellot(Spaarne Ziekenhuis), C. van Krimpen(Reinier de Graaf Hospital), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Marc J. van de Vijver(Academic Medical Center), Sabine C. Linn(The Netherlands Cancer Institute)
Cited by 278
Abstract
Related Papers
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
|The Lancet|2005|7.6k